Review article: New receptor targets for medical therapy in irritable bowel syndrome

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 1, 2010, Pages 35-46

  Camilleri, M ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASIMADOLINE; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CISAPRIDE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEXLOXIGLUMIDE; GABAPENTIN; GUANYLATE CYCLASE; LUBIPROSTONE; MESALAZINE; QUETIAPINE; RAMOSETRON; SEROTONIN 4 AGONIST; SOLABEGRON; TACHYKININ DERIVATIVE; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD;

ABDOMINAL PAIN; ANALGESIA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENTERITIS; HUMAN; HYPERALGESIA; HYPERLIPIDEMIA; IRRITABLE COLON; MAST CELL; MEDLINE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ALPROSTADIL; BILE; GASTROINTESTINAL MOTILITY; HUMANS; IRRITABLE BOWEL SYNDROME; QUALITY OF LIFE; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN AGONISTS; TREATMENT OUTCOME;

EID: 71549121350     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04153.x     Document Type: Review

References (91)

1. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol 2009 10 : S1 35.
2. Camilleri M, Chang L. Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology 2008 135 : 1877 1891.
3. Warr D. The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy. Expert Opin Pharmacother 2006 7 : 1653 1658.
4. Diemunsch P, Joshi GP, Brichant JF. Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting. Br J Anaesth 2009 103 : 7 13.
5. Grunberg SM, Rolski J, Strausz J, et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009 10 : 549 558.
6. Oh-Young L, Manakata J, Naliboff B. A double-blind, parallel group pilot study of the effects of CJ-11974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. Gastroenterology 2000 118 : A846.
7. Houghton LA, Cremonini F, Camilleri M, et al. Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol Motil 2007 19 : 732 743.
8. Dukes GE, Dewit OE, Sanger GJ, et al. Lack of effect of the NH3 receptor antagonist, talnetant SB223412, on symptoms of IBS: results of 2 randomized, double-blind, placebo-controlled dose-ranging trials. Gastroenterology 2007 132 : A60.
9. Lordal M, Navalesi G, Theodorsson E, Maggi CA, Hellstrom PM. A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br J Pharmacol 2001 134 : 215 223.
10. Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998 42 : 845 849.
11. Sagami Y, Shimada Y, Tayama J, et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004 53 : 958 964.
12. Wallon C, Söderholm JD. Corticotropin-releasing hormone and mast cells in the regulation of mucosal barrier function in the human colon. Ann N Y Acad Sci 2009 1165 : 206 210.
13. Wallon C, Yang PC, Keita AV, et al. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008 57 : 50 8.
14. Tayama J, Sagami Y, Shimada Y, Hongo M, Fukudo S. Effect of alpha-helical CRH on quantitative electro-encephalogram in patients with irritable bowel syndrome. Neurogastroenterol Motil 2007 19 : 471 483.
15. Sweetser S, Camilleri M, Linker Nord SJ, et al. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J Physiol 2009 296 : G1299 306.
16. Thoua NM, Hobson AR, Dukes GE, et al. The selective CRF-1 receptor antagonist GW876008 attenuates stress induced rectal hypersensitivity in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil 2009 21 (Suppl. 85. (abstract)
17. Duke GE, Mayer EA, Kelleher DL, Hicks KJ, Boardley RL, Alpers DH. A randomised, double blind, placebo (PLA) controlled, crossover study to evaluate the efficacy and safety of the corticotrophin releasing factor 1 (CRF1) receptor antagonist (RA) GW876008 in irritable bowel syndrome (IBS) patients. Neurogastroenterol Motil 2009 21 (Suppl. 84. (abstract)
18. Drossman DA, Danilewitz M, Naesdal J, Hwang C, Adler J, Silberg DG. Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome. Am J Gastroenterol 2008 103 : 2562 2569.
19. Pharmabiz. com. Forest to discontinue development in U.S. of dexloxiglumide for irritable bowel syndrome. 2004. October. Available at: http://www.pharmabiz.com/article/detnews.asp?articleid=18255§ionid=14 (accessed 6 October 2009).
20. Cremonini F, Camilleri M, McKinzie S, et al. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol 2005 100 : 652 663.
21. Whorwell PJ, Pace F, D'Amato M, et al. A phase III, 6 month, double-blind, placebo-controlled, randomized withdrawal trial of the selective CCK 1 antagonist dexloxiglumide in constipation-predominant IBS: the Darwin study. Gastroenterology 2008 134 : A-157 (abstract).
22. Cellek S, Thangiah R, Bassil AK, et al. Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system. Gastroenterology 2007 133 : 175 183.
23. Grudell AB, Camilleri M, Jensen KL, et al. Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. Am J Physiol 2008 294 : G1114 9.
24. Kelleher DL, Hicks KJ, Cox DS, Williamson RR, Alpers DH, Dukes GE. Randomized, double-blind, placebo (PLA)-controlled, crossover study to evaluate efficacy and safety of the beta 3-adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil 2008 20 (Suppl. 1 131 132. (abstract)
25. Mayer EA, Bradesi S, Chang L, Spiegel BM, Bueller JA, Naliboff BD. Functional GI disorders: from animal models to drug development. Gut 2008 57 : 384 404.
26. Chial HJ, Camilleri M, Ferber I, et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003 1 : 211 218.
27. De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008 20 : 99 112.
28. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991 67 : 774 776.
29. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001 120 : 354 360.
30. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008 358 : 2344 2354.
31. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009 29 : 315 328.
32. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009 58 : 357 365.
33. Camilleri M, Kerstens R, Beyens G, Robinson P, Vandeplassche L. A double-blind, placebo controlled trial to evaluate the safety and tolerability of prucalopride oral solution in constipated elderly patients living in a nursing facility. Gastroenterology 2009 136 (Suppl. 1 240.
34. Camilleri M, Beyens G, Kerstens R, Vandeplassche L. Long-term follow up of safety and satisfaction with bowel function in response to oral prucalopride in patients with chronic constipation. Gastroenterology 2009 136 (Suppl. 1 160.
35. Dennis D, Palme M, Irwin I, Druzgala P, Teichman S. ATI-7505 is a novel, selective 5HT(4) receptor agonist that causes gastrointestinal prokinetic activity in dogs. Gastroenterology 2004 126 : A641.
36. Camilleri M, Vazquez-Roque MI, Burton D, et al. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007 19 : 30 8.
37. Johnson AC, Tyler KR, Palme M, Greenwood-Van Meerveld B. Efficacy of ATI-7505, a novel highly selective 5-HT4 receptor agonist, in a rodent model. Gastroenterology 2009 136 (Suppl. 1 158.
38. Smith JA, Beattie DT, Marquess D, et al. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008 378 : 125 137.
39. Beattie DT, Armstrong SR, Shaw JP, et al. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008 378 : 139 147.
40. Camilleri M, Manini M, McKinzie S, et al. Dose-related effects of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity, on gastrointestinal (GI) and colonic transit in healthy volunteers. Neurogastroenterol Motil 2008 20 (Suppl. 2 6.
41. Goldberg MR, Li Y-P, Pitzer K, et al. TD-5108, a selective 5-HT4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation. Gastroenterology 2008 133 : A547.
42. Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS. Inflammopharmacol 2007 15 : 5 9.
43. Hirata T, Keto Y, Nakata M, et al. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil 2008 20 : 557 565.
44. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008 77 : 225 235.
45. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 2008 43 : 1202 1211.
46. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006 130 : 34 43.
47. Kerckhoffs AP, Ter Linde JJ, Akkermans LM, Samsom M. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients. Neurogastroenterol Motil 2008 20 : 900 907.
48. Brown P, Jackson J, Shi Z-C, et al. LX1031: a new approach for managing irritable bowel syndrome (IBS). Gastroenterology 2009 136 (Suppl. 1 237.
49. Barrett KE, Keely SJ. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol 2000 62 : 535 572.
50. Mangel AW, Chaturvedi P. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 2008 78 : 180 186.
51. Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol 2004 287 : C1173 83.
52. Bassil AK, Borman RA, Jarvie EM, et al. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol 2008 154 : 126 135.
53. Cuppoletti J, Malinowska DH, Chakrabarti J, Ueno R. Effects of lubiprostone on human uterine smooth muscle cells. Prostaglandins Other Lipid Mediat 2008 86 : 56 60.
54. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol 2006 290 : G942 7.
55. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008 27 : 685 696.
56. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009 29 : 329 341.
57. Sweetser S, Busciglio IA, Camilleri M, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol 2009 296 : G295 301.
58. Vaandrager AB. Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C. Mol Cell Biochem 2002 230 : 73 83.
59. Bueno L, Beaufrand C, Mahajan-Miklos S, Bryant AP, Currie MG. Antinociceptive actions of MD-1100, a novel therapeutic agent for C-IBS, in animal models of visceral pain. Am J Gastroenterol 2004 99 : S283.
60. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation- predominant irritable bowel syndrome. Gastroenterology 2007 133 : 761 768.
61. Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009 104 : 125 132.
62. Johnston J, MacDougall J, Lavins B, et al. Linaclotide significantly improved abdominal pain, constipation and global assessments in adults with irritable bowel syndrome with constipation: results form a large twelve-week, randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2008 103 : S460 1.
63. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999 159 : 2647 2658.
64. Mekhjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest 1971 50 : 1569 1577.
65. Wingate DL, Phillips SF, Hofmann AF. Effect of glycine-conjugated bile acids with and without lecithin on water and glucose absorption in perfused human jejunum. J Clin Invest 1973 52 : 1230 1236.
66. Kirwan WO, Smith AN, Mitchell WD, Falconer JD, Eastwood MA. Bile acids and colonic motility in the rabbit and the human. Gut 1975 16 : 894 902.
67. Bampton PA, Dinning PG, Kennedy ML, Lubowski DZ, Cook IJ. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol 2002 282 : G443 9.
68. Odunsi ST, Camilleri M, Busciglio IA, et al. Effects of chenodeoxycholic acid on gastrointestinal and colonic transit and bowel function in healthy volunteers. Gastroenterology 2009 136 (Suppl. 1 T1247.
69. Bazzoli F, Malavolti M, Petronelli A, Barbara L, Roda E. Treatment of constipation with chenodeoxycholic acid. J Int Med Res 1983 11 : 120 123.
70. Bell GD, Mok HY, Thwe M, et al. Liver structure and function in cholelithiasis: effect of chenodeoxycholic acid. Gut 1974 15 : 165 172.
71. Sinha L, Liston R, Testa HJ, Moriarty KJ. Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine. Aliment Pharmacol Ther 1998 12 : 839 844.
72. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999 159 : 1893 1900.
73. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008 168 : 1531 1540.
74. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008 31 : 1479 1484.
75. Fernández-Bañares F, Esteve M, Salas A, et al. Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics. Am J Gastroenterol 2007 102 : 2520 2528.
76. Camilleri M, Nadeau A, Tremaine WJ, et al. Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil 2009 21 : 734 739.
77. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009 136 : 1979 1988.
78. Lobo B, Vicario M, Martinez C, et al. Clinical benefit in IBS after disodium cromoglycate involves mast cell-mediated recovery of healthy-like innate immunity genes expression profile in the jejunal mucosa. Gastroenterology 2009 136 (Suppl. 1 156.
79. The FO, Buist MR, Lei A, et al. The role of mast cell stabilization in treatment of postoperative ileus: a pilot study. Am J Gastroenterol 2009 104 : 2257 2266.
80. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004 126 : 693 702.
81. Klooker TK, Koopman KE, Heide S, Wijngaard RM, Boeckxstaens GE Treatment with the mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in IBS patients. Proceedings of the United European Gastroenterology Federation (UEGF) Meeting, Vienna, Austria, 2008, pp. OP397.
82. Corinaldesi R, Stanghellini V, Cremon C, et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof of concept study. Aliment Pharmacol Ther 2009 30 : 245 252.
83. Delgado-Aros S, Chial HJ, Camilleri M, et al. Effects of a kappa opioid agonist, asimadoline, on satiation and gastrointestinal motor and sensory functions in humans. Am J Physiol 2003 284 : G558 66.
84. Mangel AW, Bornstein JD, Hamm LR, et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008 28 : 239 249.
85. Szarka LA, Camilleri M, Burton D, et al. Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol 2007 5 : 1268 1275.
86. Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2005 22 : 981 988.
87. Houghton LA, Fell C, Whorwell PJ, et al. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007 56 : 1218 1225.
88. Leventer SM, Raudibaugh K, Frissora CL, et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther 2008 27 : 197 206.
89. Grover M, Dorn SD, Weinland SR, Dalton CB, Gaynes BN, Drossman DA. Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. Dig Dis Sci 2009 54 : 1284 1291.
90. Talley NJ. Green light from the FDA for new drug development in irritable bowel syndrome and functional dyspepsia. Am J Gastroenterol 2009 104 : 1339 1341.
91. Camilleri M, McKinzie S, Busciglio I, et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008 6 : 772 778.